Polyrizon (NASDAQ:PLRZ) Trading 11.1% Higher – Time to Buy?

Shares of Polyrizon Ltd. (NASDAQ:PLRZGet Free Report) rose 11.1% on Monday . The company traded as high as $12.75 and last traded at $12.75. Approximately 18,708 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 34,144 shares. The stock had previously closed at $11.48.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on PLRZ shares. Weiss Ratings lowered shares of Polyrizon from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. Wall Street Zen upgraded shares of Polyrizon from a “sell” rating to a “hold” rating in a report on Sunday, June 7th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Polyrizon presently has a consensus rating of “Sell”.

Read Our Latest Analysis on PLRZ

Polyrizon Stock Up 1.3%

The business has a fifty day moving average of $13.87 and a 200-day moving average of $13.09.

Polyrizon (NASDAQ:PLRZGet Free Report) last issued its earnings results on Saturday, February 14th. The company reported ($2.81) earnings per share for the quarter.

Institutional Trading of Polyrizon

An institutional investor recently bought a new stake in Polyrizon stock. Jane Street Group LLC bought a new position in shares of Polyrizon Ltd. (NASDAQ:PLRZFree Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned approximately 1.35% of Polyrizon at the end of the most recent reporting period.

About Polyrizon

(Get Free Report)

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

Featured Stories

Receive News & Ratings for Polyrizon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polyrizon and related companies with MarketBeat.com's FREE daily email newsletter.